• Ichnos Sciences is a new bio­technology com­pany which is a spin-off of Glenmark Holding SA created to focus on inno­va­tion
• Pipeline in­cludes five novel, first-in-class clin­i­cal-stage assets in on­col­ogy, auto­immune dis­ease and pain
• Company assets in­clude: BEAT® (Bispecific Engagement by Antibodies based on the T cell re­cep­tor), a pro­pri­e­tary plat­form; a devel­op­ment site, two research centers; a GMP biologics manu­fac­tur­ing facility and ~350 employees world­wide

Paramus, NJ (Press Release) – Ichnos ('īk-nōz) Sciences officially opened its doors to the world today as an independent, fully integrated, global bio­tech com­pany. A spin-off of Glenmark Holding SA, a global pharma­ceu­tical com­pany with a track-record of im­prov­ing patients' lives by providing affordable med­i­cines, the newly formed com­pany was first approved in principle by the Glenmark Board of Directors in Feb­ru­ary 2019 and now operates with its own board of directors …

GBR 1342 to be devel­oped by Glenmark Pharma­ceu­ticals' spinoff inno­va­tion com­pany

Mahwah, NJ (Press Release) – Glenmark Pharma­ceu­ticals (Glenmark), a research-led, integrated global pharma­ceu­tical com­pany, today announced that the U.S. Food and Drug Admin­istra­tion (FDA) has granted Orphan Drug Desig­na­tion to its bispecific anti­body can­di­date GBR 1342 for the treat­ment of patients with multiple myeloma who have received prior ther­a­pies. Derived from the com­pany's pro­pri­e­tary BEAT® (Bispecific Engagement by Antibodies based on the T cell re­cep­tor) tech­nology, GBR 1342 is being in­ves­ti­gated for the treat­ment of multiple myeloma. The can­di­date is one of five clin­i­cal-stage assets in the pipe­line of Glenmark's new inno­va­tion …